Advertisement

Medication-Induced Neurotoxicity in Critically Ill Cancer Patients

  • Monica E. LoghinEmail author
  • Anne Kleiman
Reference work entry

Abstract

Neurotoxicity associated with cancer treatment and treatment for medical and surgical complications of cancer have been well recognized. Elderly patients, advanced cancer, concomitant polypharmacy, organ failure, and medical comorbidities are all confounders contributing to adverse events related to cancer therapy. Short-term and long-term neurotoxicities may lead to disabilities and poor quality of life in patients with cancer. As a result of early detection of cancer and advances in treatment, cancer survival rates have improved consistently over the last decades and thus long-term survivors may face physical and psychological challenges associated with cancer and cancer treatment. As such, understanding the pathogenic mechanisms, optimizing the strategies for clinical assessment and interventions for the management and prevention of medication-related neurotoxicity is of paramount importance in patient care.

This chapter will address the neurotoxicity induced by a number of drug classes commonly used in the treatment of cancer patients.

Keywords

Chemotherapy Opiates Antiepileptic drugs Immunosuppressive drugs 

References

  1. 1.
    Magge RS, DeAngelis LM. The double-edged sword: neurotoxicity of chemotherapy. Blood Rev. 2015;29:93–100.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Robertson GL, Bhoopalam N, Zelkowitz LI. Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Arch Intern Med. 1973;132:717–20.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Whittaker JA, Parry DH, Bunch C, Weatherall DJ. Coma associated with vincristine therapy. Br Med J. 1973;4:335–7.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Boranic M, Raci F. A Parkinson-like syndrome as side effect of chemotherapy with vincristine and adriamycin in a child with acute leukaemia. Biomedicine. 1979;31:124–5.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Byrd RL, Rohrbaugh TM, Raney RB Jr, Norris DG. Transient cortical blindness secondary to vincristine therapy in childhood malignancies. Cancer. 1981;47:37–40.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Dallera F, Gamoletti R, Costa P. Unilateral seizures following vincristine intravenous injection. Tumori. 1984;70:243–4.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Scheithauer W, Ludwig H, Maida E. Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report. Investig New Drugs. 1985;3:315–8.CrossRefGoogle Scholar
  8. 8.
    Hurwitz RL, Mahoney DH, Armstrong DL, Browder TM. Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol. 1988;16:216–9.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Gaidys WG, Dickerman JD, Walters CL, Young PC. Report of a fatal case despite CNS washout. Cancer. 1983;52:799–801.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Walther PJ, Rossitch E, Bullard DE. The development of Lhermitte’s sign during cisplatin chemotherapy. Possible drug-induced toxicity causing spinal cord demyelination. Cancer. 1987;60:2170–2.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    DeAngelis LM, Posner JB. Neurologic complications of cancer. 2nd ed. Oxford: Oxford University Press; 2009.Google Scholar
  12. 12.
    Wasner G, Hilpert F, Schattschneider J, Binder A, Pfisterer J, Baron R. Docetaxel-induced nail changes – a neurogenic mechanism: a case report. J Neuro-Oncol. 2002;58:167–74.CrossRefGoogle Scholar
  13. 13.
    Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2001:CD005228.  https://doi.org/10.1002/14651858.CD005228.pub3; 1–48
  14. 14.
    Chabner B, Longo DL. Cancer chemotherapy and biotherapy: principles and practice. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.Google Scholar
  15. 15.
    Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med. 2009;219:177–86.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Icli F, Karaoguz H, Dincol D, Demirkazik A, Gunel N, Karaoguz R, Oner A. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 1993;72:587–93.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Lyass O, Lossos A, Hubert A, Gips M, Peretz T. Cisplatin-induced non-convulsive encephalopathy. Anti-Cancer Drugs. 1998;9:100–4.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Renard D, Westhovens R, Vandenbussche E, Vandenberghe R. Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol. 2004;251:226–8.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Kiewe P, Seyfert S, Korper S, Rieger K, Thiel E, Knauf W. Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy. Leuk Lymphoma. 2003;44:1815–8.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Benger A, Browman GP, Walker IR, Preisler HD. Clinical evidence of a cumulative effect of high-dose cytarabine on the cerebellum in patients with acute leukemia: a leukemiaintergroup report. Cancer Treat Rep. 1985;6:240–1.Google Scholar
  21. 21.
    Scherokman B, Filling-Katz MR, Tell D. Brachial plexus neuropathy following high-dose cytarabine in acute monoblastic leukemia. Cancer Treat Rep. 1985;69:1005–6.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Borgeat A, De Muralt B, Stalder M. Peripheral neuropathy associated with high-dose Ara-C therapy. Cancer. 1986;58:852–4.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Nagarajan R, Peters C, Orchard P, Rydholm N. Report of severe neurotoxicity with cyclophosphamide. J Pediatr Hematol Oncol. 2000;22:544–6.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Kende G, Sirkin SR, Thomas PR, Freeman AI. Blurring of vision: a previously undescribed complication of cyclophosphamide therapy. Cancer. 1979;44:69–71.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005;11:6767–71.CrossRefGoogle Scholar
  26. 26.
    Pachman DR, Weisbrod BL, Seisler DK, Barton DL, Fee-Schroeder KC, Smith TJ, Lachance DH, Liu H, Shelerud RA, Cheville AL, Loprinzi CL. Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2015;23:943–51.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Hu LY, Mi WL, Wu GC, Wang YQ, Mao-Ying QL. Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms. Curr Neuropharmacol. 2017;  https://doi.org/10.2174/1570159X15666170915143217.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Park SB, Goldstein D, Krishman AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. Cancer J Clin. 2013;63:419–37.CrossRefGoogle Scholar
  29. 29.
    Quigley C, Joel S, Patel N, Baksh A, Slevin M. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med. 2003;17:185–90.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Ripamonti C, Dickerson ED. Strategies for the treatment of cancer pain in the new millennium. Drugs. 2001;61:955–77.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Grond S, Zech D, Diefenbach C, Bischoff A. Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manag. 1994;9:372–82.CrossRefGoogle Scholar
  32. 32.
    Oosten AW, Oldenmenger WH, Mathijssen RH, van der Rijt CC. A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures. J Pain. 2015;16:935–46.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    De Conno F, Ripamonti C, Fagnoni E, Brunelli C, Luzzani M, Maltoni M, Arcuri E, Bertetto O. The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during ‘titration phase’ in patients with cancer pain. Palliat Med. 2008;22:214–21.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Mercadante S, Casuccio A, Agnello A, Serreta R, Calderone L, Baressi L. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J Clin Oncol. 1998;16:3656–61.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Lawlor PG. The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal. Cancer. 2002;94:1836–53.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Hagen N, Swanson R. Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies. J Pain Symptom Manag. 1997;14:51–8.CrossRefGoogle Scholar
  37. 37.
    Folstein MF, Fetting JH, Lobo A, Naiz U, Capozzoli KD. Cognitive assessment of cancer patients. Cancer. 1984;53:2250–7.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend. 2001;63:139–46.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Lotsch J. Opioid metabolites. J Pain Symptom Manag. 2005;29:S10–24.CrossRefGoogle Scholar
  40. 40.
    Kaiko RF, Foley KM, Grabinski PY, Heidrich G, Rogers AG, Inturissi CE, Reidenberg MM. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol. 1983;13:180–5.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Ripamonti C, Bianchi M. The use of methadone for cancer pain. Hematol Oncol Clin North Am. 2002;16:543–55.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Morita T, Tei Y, Tsunoda J, Inoue S, Chihara S. Underlying pathologies and their associations with clinical features in terminal delirium of cancer patients. J Pain Symptom Manag. 2001;22:997–1006.CrossRefGoogle Scholar
  43. 43.
    Slatkin N, Rhiner M. Treatment of opioid-induced delirium with acetylcholinesterase inhibitors: a case report. J Pain Symptom Manag. 2004;27:268–73.CrossRefGoogle Scholar
  44. 44.
    Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain. 1998;74:5–9.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Li X, Angst MS, Clark JD. A murine model of opioid-induced hyperalgesia. Brain Res Mol Brain Res. 2001;86:56–62.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician. 2009;12:679–84.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Ross JR, Riley J, Quigley C, Welsh KI. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist. 2006;11:765–73.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Cherny NI. The management of cancer pain. CA Cancer J Clin. 2000;50:70–116, quiz 117–20.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Bromfield EB. Epilepsy in patients with brain tumors and other cancers. Rev Neurol Dis. 2004;1(Suppl 1):S27–33.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, Williamson PD, Treiman DM, McNamara JO, McCutchen CB. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985;313:145–51.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3:159–68.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Arif H, Buchsbaum R, Weintraub D, Pierro J, Resor SR Jr, Hirsch LJ. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav. 2009;14:202–9.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Karas BJ, Wilder BJ, Hammond EJ, Bauman AW. Valproate tremors. Neurology. 1982;32:428–32.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Jamora D, Lim SH, Pan A, Tan L, Tan EK. Valproate-induced Parkinsonism in epilepsy patients. Mov Disord. 2007;22:130–3.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Kokenge R, Kutt H, McDowell F. Neurological sequelae following Dilantin overdose in a patient and in experimental animals. Neurology. 1965;15:823–9.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Munoz-Garcia D, Del Ser T, Bermejo F, Portera A. Truncal ataxia in chronic anticonvulsant treatment. Association with drug-induced folate deficiency. J Neurol Sci. 1982;55:305–11.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    De Marcos FA, Ghizoni E, Kobayashi E, Li LM, Cendes F. Cerebellar volume and long-term use of phenytoin. Seizure. 2003;12:312–5.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Hamed SA, Abdellah MM. The relationship between valproate induced tremors and circulating neurotransmitters: a preliminary study. Int J Neurosci. 2017;127:236–42.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Armon C, Shin C, Miller P, Carwile S, Brown E, Edinger JD, Paul RG. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology. 1996;47:626–35.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Meador KJ, Loring DW, Moore EE, Thompson WO, Nichols ME, Oberzan RE, Durkin MW, Gallagher BB, King DW. Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults. Neurology. 1995;45:1494–9.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia. 1996;37(Suppl 2):S18–22.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Alonso-Juarez M, Torres-Russotto D, Crespo-Morfin P, Baizabal-Carvallo JF. The clinical features and functional impact of valproate-induced tremor. Parkinsonism Relat Disord. 2017;44:147–50.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Relling MV, Pui CH, Sandlund JT, Rivera GK, Hancock ML, Boyett JM, Schuetz EG, Evans WE. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet. 2000;356:285–90.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Reardon DA, Vredenburgh JJ, Desjardins A, Peters KB, Sathornsumetee S, Threatt S, Sampson JH, Herndon JE, Coan A, McSherry F, Rich JN, McLendon RE, Zhang S, Friedman HS. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neuro-Oncol. 2012;108:499–506.CrossRefGoogle Scholar
  65. 65.
    Avila EK, Graber J. Seizures and epilepsy in cancer patients. Curr Neurol Neurosci Rep. 2010;10:60–7.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Bartynski WS, Zeigler Z, Spearman MP, Lin L, Shadduck RK, Lister J. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. AJNR Am J Neuroradiol. 2001;22:1901–14.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Wijdicks EF, Wiesner RH, Dahlke LJ, Krom RA. FK506-induced neurotoxicity in liver transplantation. Ann Neurol. 1994;35:498–501.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Masetti R, Cordelli DM, Zama D, Vendemini F, Baigi C, Franzoni E, Pession A. PRES in children undergoing hematopoietic stem cell or solid organ transplantation. Pediatrics. 2015;135:890–901.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Wijdicks EF. Neurotoxicity of immunosuppressive drugs. Liver Transpl. 2001;7:937–42.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Ayres RC, Dousset B, Wixon S, Buckels JA, McMaster P, Mayer AD. Peripheral neurotoxicity with tacrolimus. Lancet. 1994;343:862–3.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Chohan R, Vij R, Adkins D, Blum W, Brown R, Tomasson M, Devine S, Graubert T, Goodnough LT, Dipersio JF, Khoury H. Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity. Br J Haematol. 2003;123:110–3.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Nishiguchi T, Mochizuki K, Shakudo M, Takeshita T, Hino M, Inoue Y. CNS complications of hematopoietic stem cell transplantation. AJR Am J Roentgenol. 2009;192:1003–11.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Marra A, Vargas M, Striano P, Del Guercio L, Buonanno P, Servillo G. Posterior reversible encephalopathy syndrome: the endothelial hypotheses. Med Hypotheses. 2014;82:619–22.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Baumgartel K, Mansuy IM. Neural functions of calcineurin in synaptic plasticity and memory. Learn Mem. 2012;19:375–84.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Wijdicks EF, Dahlke LJ, Wiesner RH. Oral cyclosporine decreases severity of neurotoxicity in liver transplant recipients. Neurology. 1999;52:1708–10.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Filley CM, Kleinschmidt-DeMasters BK. Toxic leukoencephalopathy. N Engl J Med. 2001;345:425–32.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85:427–32.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Kamiya-Matsuoka C, Paker AM, Chi L, Youssef A, Tummala S, Loghin ME. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neuro-Oncol. 2016;128:75–84.CrossRefGoogle Scholar
  79. 79.
    Lamy C, Oppenheim C, Meder JF, Mas JF. Neuroimaging in posterior reversible encephalopathy syndrome. J Neuroimaging. 2014;14:89–96.CrossRefGoogle Scholar
  80. 80.
    Pinedo DM, Shah-Khan F, Shah PC. Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin. J Clin Oncol. 2007;25:5320–1.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson WE, Garrity L, Jagoda A, Lowenstein D, Pellock J, Riviello J, Sloan E, Treiman DM. Epilepsy based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. Epilepsy Curr. 2016;16:48–61.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020

Authors and Affiliations

  1. 1.Department of Neuro-OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Section editors and affiliations

  • Yenny Cardenas
    • 1
  1. 1.Critical Care DepartmentUniversidad del Rosario Hospital Universitario Fundacion Santa Fe deBogotaColombia

Personalised recommendations